Patents by Inventor Anna Ayres

Anna Ayres has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hepatitis B viral variants with reduced susceptibility to nucleoside analogs and uses thereof
    Patent number: 7846663
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: December 7, 2010
    Assignees: Melbourne Health, Austin Health
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Danielle Colledge, Joseph Sasadeusz, Peter William Angus, William Sievert
  • HEPATITIS B VIRAL VARIANTS WITH REDUCED SUSCEPTIBILITY TO NUCLEOSIDE ANALOGS AND USES THEREOF
    Publication number: 20100304392
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Application
    Filed: June 1, 2010
    Publication date: December 2, 2010
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Danielle Colledge, Joseph Sasadeusz, Peter William Angus, William Sievert
  • Hepatitis B viral variants with reduced susceptibility to nucleoside analogs and uses thereof
    Patent number: 7745130
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Grant
    Filed: September 25, 2007
    Date of Patent: June 29, 2010
    Assignees: Melborne Health, Austin Health, Southern Health
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Danielle Colledge, Joseph Sasadeusz, Peter William Angus, William Sievert
  • DETECTION AND USE OF ANTIVIRAL RESISTANCE MUTATIONS
    Publication number: 20100075299
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. Vaccines and diagnostic assays are also contemplated herein.
    Type: Application
    Filed: June 4, 2007
    Publication date: March 25, 2010
    Applicants: MELBOURNE HEALTH, AUSTIN HEALTH, BAYSIDE HEALTH, ST.VINCENT'S HOSPITAL (MELBOURNE) LTD. TRADING AS ST. VINCENT'S HOSPITAL MELBOURNE, SOUTHERN HEALTH
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayre, Lilly Ka Wai Yuen, Peter William Angus, Joseph John Sasadeusz, Paul Desmond, Hans Tillman, Thomas Bock, William Sievert, Sharon Lewin
  • HEPATITIS B VIRUS DNA POLYMERASE AND SURFACE ANTIGEN VARIANTS AND METHODS OF USING SAME
    Publication number: 20090155771
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to agents and in particular nucleoside analogues. More particularly, the present invention is directed to hepatitis B virus variants exhibiting complete or partial resistance to nucleoside analogues. The variants may also comprise corresponding mutations affecting immunological interactivity to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes and in developing new or modified vaccines directed against viral agents and in particular hepatitis B virus variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Application
    Filed: October 6, 2008
    Publication date: June 18, 2009
    Applicants: Melbourne Health, Austin and Repatriation Medical Centre, Central Sydney Area Health Service
    Inventors: Angeline Ingrid BARTHOLOMEUSZ, Stephen Alister Locarnini, Anna Ayres, Margaret Rose Littlejohn, Geoffrey William McCaughan, Peter William Angus
  • VARIANTS OF HEPATITIS B VIRUS WITH RESISTANCE TO ANTI-VIRAL NUCLEOSIDE AGENTS AND APPLICATIONS THEREOF
    Publication number: 20090130651
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Application
    Filed: April 4, 2006
    Publication date: May 21, 2009
    Applicant: Melbourne Health
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Locarmini, Anna Ayres, Margaret Littlejohn, Paul Desmond, Peter William Angus
  • Viral Variants With Altered Susceptibility To Nucleoside Analogs And Uses Thereof
    Publication number: 20090081667
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Application
    Filed: June 20, 2008
    Publication date: March 26, 2009
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Peter William Angus, William Sievert
  • Hepatitis B Viral Variants With Reduced Susceptibility To Nucleoside Analogs And Uses Thereof
    Publication number: 20090081637
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Application
    Filed: September 25, 2007
    Publication date: March 26, 2009
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Danielle Colledge, Joseph Sasadeusz, Peter William Angus, William Sievert
  • HEPATITIS B VIRAL VARIANTS WITH REDUCED SUSCEPTIBILITY TO NUCLEOSIDE ANALOGS AND USES THEREOF
    Publication number: 20090053201
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Application
    Filed: October 31, 2007
    Publication date: February 26, 2009
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Danielle Colledge, Joseph Sasadeusz, Peter William Angus, William Sievert
  • Antiviral Resistance Mutants and Applications Thereof
    Publication number: 20080274083
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to agents such as nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Application
    Filed: October 20, 2006
    Publication date: November 6, 2008
    Applicants: Melbourne Health, Austin Health
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayres, Margaret Littlejohn, Peter William Angus
  • Hepatitis B virus DNA polymerase and surface antigen variants and methods of using same
    Patent number: 7431933
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to agents and in particular nucleoside analogues. More particularly, the present invention is directed to hepatitis B virus variants exhibiting complete or partial resistance to nucleoside analogues. The variants may also comprise corresponding mutations affecting immunological interactivity to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes and in developing new or modified vaccines directed against viral agents and in particular hepatitis B virus variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: October 7, 2008
    Assignees: Melbourne Health, Austin and Repatriation Medical Centre, Central Sydney Area Health Service
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Margaret Rose Littlejohn, Geoffrey William McCaughan, Peter William Angus
  • Viral variants with altered susceptibility to nucleoside analogs and uses thereof
    Patent number: 7405039
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Grant
    Filed: August 4, 2004
    Date of Patent: July 29, 2008
    Assignees: Austin Health, Melbourne Health
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Peter William Angus, William Sievert
  • VARIANTS OF HEPATITIS B VIRUS WITH RESISTANCE TO ANTI-VIRAL NUCLEOSIDE AGENTS AND APPLICATIONS THEREOF
    Publication number: 20080176218
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Application
    Filed: October 31, 2007
    Publication date: July 24, 2008
    Applicants: Melbourne Health, St. Vincent's Hospital (Melbourne) Ltd. trading as St. Vincent's Hospital Melbourne, Austin Health
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayres, Margaret Littlejohn, Paul Desmond, Peter William Angus
  • Viral variants
    Publication number: 20080171313
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus variants exhibiting complete or partial resistance to nucleoside analogues and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes and in developing new or modified vaccines directed against viral agents and in particular hepatitis B virus variants.
    Type: Application
    Filed: October 5, 2007
    Publication date: July 17, 2008
    Applicant: MELBOURNE HEALTH
    Inventors: Angeline Bartholomeusz, Margaert Littlejohn, Anna Ayres, Stephen Locarnini
  • Hepatitis B viral variants with reduced susceptibility to nucleoside analogs and uses thereof
    Patent number: 7384747
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Grant
    Filed: June 24, 2005
    Date of Patent: June 10, 2008
    Assignees: Melbourne Health, Austin Health
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Danielle Colledge, Joseph Sasadeusz, Peter William Angus, William Sievert
  • Viral variants
    Patent number: 7291453
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus variants exhibiting complete or partial resistance to nucleoside analogues and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes and in developing new or modified vaccines directed against viral agents and in particular hepatitis B virus variants.
    Type: Grant
    Filed: April 9, 2000
    Date of Patent: November 6, 2007
    Assignee: Melbourne Health
    Inventors: Angeline Bartholomeusz, Margaret Littlejohn, Anna Ayres, Stephen Locarnini
  • Hbv Variants Detection and Application
    Publication number: 20070243213
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Application
    Filed: October 20, 2004
    Publication date: October 18, 2007
    Inventors: Angeline Bartholomeusz, Stephen Locarnini, Anna Ayres, Lilly Yuen, Joseph Sasadeusz
  • Hepatitis B viral variants with reduced susceptibility to nucleoside analogs and uses thereof
    Publication number: 20060051743
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Application
    Filed: June 24, 2005
    Publication date: March 9, 2006
    Inventors: Angeline Bartholomeusz, Stephen Locarnini, Anna Ayres, Danielle Colledge, Joseph Sasadeusz, Peter Angus, William Sievert
  • Viral variants with altered susceptibility to nucleoside analogs and uses thereof
    Publication number: 20050153279
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Application
    Filed: August 4, 2004
    Publication date: July 14, 2005
    Inventors: Angeline Bartholomeusz, Stephen Locarnini, Anna Ayres, Peter Angus, William Sievert
  • Hepatitis b virus dna polymerase and surface antigen variants and methods of using same
    Publication number: 20040005541
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to agents and in particular nucleoside analogues. More particularly, the present invention is directed to hepatitis B virus variants exhibiting complete or partial resistance to nucleoside analogues. The variants may also comprise corresponding mutations affecting immunological interactivity to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes and in developing new or modified vaccines directed against viral agents and in particular hepatitis B virus variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Application
    Filed: May 12, 2003
    Publication date: January 8, 2004
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Margaret Rose Littlejohn, Geoffrey William McCaughan, Peter William Angus